Ranbaxy Laboratories Limited is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines. Ranbaxy is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The company is headquartered in India. It has presence in 49 countries, with manufacturing facilities in 11 and a diverse product portfolio.
Ranbaxy was incorporated in 1961. Bhai Mohan Singh was the founder of
the company. He bought the company from his cousins Ranjit Singh and
Gurbax Singh. Ranbaxy's name is a fusion of Ranjit and Gurbax's names.
Ranbaxy went public in 1973. Ranbaxy's first joint venture was set up in
Lagos (Nigeria) in 1977. In 1985, Ranbaxy Research Foundation was
established and Stancare, Ranbaxy's second pharmaceutical market
division started functioning. In 1987, production started at Ranbaxy's
Toansa Plant (Punjab) and with this Ranbaxy became India's largest
manufacturer of antibiotics/antibacterials. In 1988, Ranbaxy's Toansa
Plant got US FDA approval. In 1990, Ranbaxy was granted its first US
patent, for Doxycyline. In 1993, Ranbaxy set up a joint venture in
China. In 1994, Ranbaxy established regional headquarters in UK and USA.
In the same year its GDR was listed in Luxembourgh Stock Exchange. In
1995, Ranbaxy acquired Ohm Laboratories, a manufacturing facility in the
US and inaugurated state-of-the art new manufacturing wing at Ranbaxy's
US subsidiary Ohm Laboratories Inc. In 1997, Ranbaxy crossed a sales
turnover of Rs. 10,000 million.
In 1998, Ranbaxy entered USA, world's largest pharmaceutical market,
with products under its own name. In the same year, Ranbaxy filed its
first Investigational New Drug (IND) application with the Drugs
Controller General OF India for approvals to conduct Phase 1 Clinical
trials. In 1999, Ranbaxy commenced trials for its NCE. In 2000, Ranbaxy
acquired Bayer's Generic business in Germany, and entered into Brazil,
the largest pharmaceutical market in South America. In 2001, Ranbaxy set
up a manufacturing facility in Vietnam. In 2003, Ranbaxy launched
Cefuroxime Axetil after approval from USFDA. It was the first approval
granted to any generic company for this product. In 2003, Ranbaxy and
Glaxo SmithKline Plc entered into an alliance for drug discovery and
development. In 2004, Ranbaxy acquired a wholly-owned subsidiary RPG
(Aventis) SA and began operations in France as a Top 10 generic company.
In 2005, Ranbaxy launched operations in Canada and acquired generic
product portfolio from EFARMES of Spain. In 2006, Ranbaxy acquired Be
Tabs pharmaceuticals of South Africa, unbranded generic business of GSK
in Italy & Spain, and Terapia of Romania.
Major Achievements of Ranbaxy